Envoy Medical shares surge 10.40% intraday as first 10 patients complete six-month Acclaim trial with no adverse events.

Envoy Medical (NASDAQ: COCH) rose 10.40% intraday after announcing that all 10 patients in the first stage of its pivotal Acclaim cochlear implant trial completed six-month follow-up visits with no serious adverse events. The update reinforced the device’s safety profile and aligned with the company’s timeline for FDA submission and commercialization, as highlighted by CEO Brent Lucas. The milestone, coupled with recent trial expansion, new patent issuances, and Breakthrough Device Designation (2019), signaled clinical progress and growing confidence in the investigational implant’s potential. The positive safety data and enrollment momentum supported investor optimism about Envoy’s long-term prospects in the hearing health market.